Spots Global Cancer Trial Database for carcinoma, ovarian epithelial

Every month we try and update this database with for carcinoma, ovarian epithelial cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers	NCT03976999	Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	NCT04660929	HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm...	CT-0508 Pembrolizumab	18 Years -	Carisma Therapeutics Inc
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	NCT06121401	Carcinoma, Ovar...	Olaparib Bevacizumab	18 Years - 75 Years	Mario Negri Institute for Pharmacological Research
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	NCT05544929	Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative...	KFA115 pembrolizumab	18 Years -	Novartis
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	NCT06121401	Carcinoma, Ovar...	Olaparib Bevacizumab	18 Years - 75 Years	Mario Negri Institute for Pharmacological Research
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	NCT04498117	Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop...	Oregovomab Paclitaxel Carboplatin Placebo Carboplatin	18 Years -	CanariaBio Inc.
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer	NCT05297734	End of Life Cancer	Receive technol... Receive redesig...	21 Years -	Stanford University
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers	NCT03976999	Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop...	Biological coll...	18 Years -	Institut du Cancer de Montpellier - Val d'Aurelle
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	NCT04660929	HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm...	CT-0508 Pembrolizumab	18 Years -	Carisma Therapeutics Inc
BP1001-A in Patients With Advanced or Recurrent Solid Tumors	NCT04196257	Solid Tumor, Ad... Carcinoma, Ovar... Fallopian Tube ... Endometrial Can... Peritoneal Canc... Solid Tumor	BP1001-A (Lipos... BP1001-A (Lipos...	18 Years -	Bio-Path Holdings, Inc.
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer	NCT04519151	Ovarian Neoplas... Carcinoma, Ovar... Neoplasm of Sto... Ovarian Disease... Genital Neoplas... Ovarian Epithel... Urogenital Neop... Neoplasms, Glan...	Pembrolizumab Lenvatinib	18 Years -	Sheba Medical Center
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	NCT06121401	Carcinoma, Ovar...	Olaparib Bevacizumab	18 Years - 75 Years	Mario Negri Institute for Pharmacological Research
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)	NCT05116189	Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ...	Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel	18 Years -	Merck Sharp & Dohme LLC
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer	NCT05158062	Carcinoma, Ovar...	pembrolizumab olaparib bevacizumab carboplatin paclitaxel docetaxel	20 Years -	Saitama Medical University International Medical Center
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	NCT05544929	Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative...	KFA115 pembrolizumab	18 Years -	Novartis
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)	NCT05116189	Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ...	Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel	18 Years -	Merck Sharp & Dohme LLC

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: